Deep Dive Into Globus Medical Stock: Analyst Perspectives (7 Ratings)
Portfolio Pulse from Benzinga Insights
The article provides an in-depth analysis of Globus Medical (NYSE:GMED) based on recent analyst ratings. Over the past 30 days, 7 analysts have given mixed ratings, with a majority being bullish. The average 12-month price target has increased by 9.09% to $70.0. Key analysts from firms like BTIG, Piper Sandler, and Barclays have raised their price targets, reflecting positive sentiment. Despite strong revenue growth, the company faces challenges with profitability and returns on equity and assets.
May 29, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Globus Medical has received a mix of bullish and somewhat bullish ratings from analysts, with a notable increase in the average 12-month price target to $70.0. Analysts from BTIG, Piper Sandler, and Barclays have raised their price targets, indicating positive sentiment. However, the company faces challenges with profitability and returns on equity and assets.
The majority of analysts have given bullish ratings, and the average price target has increased, indicating positive sentiment. However, the company's profitability metrics are below industry standards, which could temper the positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100